Anorexia Nervosa Genetics Initiative (ANGI)

The Anorexia Nervosa Genetics Initiative (ANGI) is an international collaboration that recruited individuals with a lifetime history of anorexia nervosa from the United States (US), Australia/New Zealand (ANZ), Sweden (SE), and Denmark (DK). Matched controls, with no history of eating disorders, were also recruited from the US, SE, and DK. Recruitment avenues included national registers (SE, DK), treatment centers (US, ANZ, SE, DK), and social and traditional media (US, ANZ, SE). Participants provided blood samples and clinical information. Diagnoses were based on DSM-IV or ICD-10 criteria (amenorrhea was not required). Genotype data are available for 12,918 participants. *NOTE: Denmark data cannot be shared openly but require prior and individual permission by the data owner: The Head of the National Center for Register Based Research Aarhus, DK. Genotyping of samples from Denmark was completed using the Illumina PsychArray (data not supplied).]]>
The datasets in this repository are a subset from the latest PGC-ED Freeze 2 AN analysis (Watson et al., 2019; PMID: 31308545). Cohort description: PGC-ED is a collaboration representing researchers and clinicians from around the world, founded with the goal of identifying the genetic risk factors involved in the etiology of anorexia nervosa (AN) and other eating disorders. The Freeze 2 AN meta-analysis sample comprises 16,992 individuals with AN and 55,525 controls from 33 cohorts. Cases met DSM-IV criteria for either lifetime AN (restricting or binge-purge subtype) or lifetime eating disorders 'not otherwise specified' AN-subtype (i.e., exhibiting the core features of AN). Detailed information on recruitment and case ascertainment can be found in Watson et al. (2019). Out of the 33 cohorts, the majority of samples came from the Anorexia Nervosa Genetics Initiative (ANGI) study, a multi-site recruitment effort in the USA, Sweden, Denmark and Australia, with assistance from New Zealand. These samples (12,537 cases post-QC) are included for the first time in an AN GWAS in the publication by Watson et al. (2019). A cohort from the UK Biobank was included and these samples also appear for the first time in an AN GWAS in this publication. The remaining cohorts were from the Genetic Consortium for Anorexia Nervosa (GCAN)/Wellcome Trust Case Control Consortium 3 (WTCCC3) and Children's Hospital of Philadelphia (CHOP)/Price Foundation Collaborative Group (PFCG). Most of the GCAN/WTCCC3 samples and CHOP/PFCG samples were in previous AN GWAS.Cases - For cases recruited from the United States, Australia/New Zealand, and Sweden, a lifetime anorexia nervosa diagnosis based on DSM-IV or ICD-10 criteria (excluding amenorrhea) was required. Lowest illness related BMI had to be below 18.55. Phenotypic data (diagnostic and symptom information) for most cases are from a self-report questionnaire (ED100K-V1). Diagnostic algorithms were developed and validated against clinical interviews. In the US, ANZ, and SE, participants with anorexia nervosa were identified from clinical services (US, ANZ, SE), media and social media (US, ANZ, SE), or national registers (SE). For Denmark, inclusion was based on national health register or clinic diagnosis of ICD-10 F50.0 (AN) or F50.1 (atypical AN). Controls - For controls recruited from the United States and Sweden, inclusion criteria were as follows: no lifetime history of eating disorder symptoms, and since age 18, BMI was never lower than 18.55. For Denmark, inclusion was based on absence of major psychiatric diagnoses in the national health registers. ]]>